206 related articles for article (PubMed ID: 16534115)
1. High-dose rituximab and anti-MAG-associated polyneuropathy.
Renaud S; Fuhr P; Gregor M; Schweikert K; Lorenz D; Daniels C; Deuschl G; Gratwohl A; Steck AJ
Neurology; 2006 Mar; 66(5):742-4. PubMed ID: 16534115
[TBL] [Abstract][Full Text] [Related]
2. Long-term effect of rituximab in anti-mag polyneuropathy.
Benedetti L; Briani C; Franciotta D; Carpo M; Padua L; Zara G; Zambello R; Sormani MP; Mancardi GL; Nobile-Orazio E; Schenone A
Neurology; 2008 Nov; 71(21):1742-4. PubMed ID: 19015493
[No Abstract] [Full Text] [Related]
3. Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M.
Benedetti L; Briani C; Grandis M; Vigo T; Gobbi M; Ghiglione E; Carpo M; Cocito D; Caporale CM; Sormani MP; Mancardi GL; Nobile-Orazio E; Schenone A
J Peripher Nerv Syst; 2007 Jun; 12(2):102-7. PubMed ID: 17565535
[TBL] [Abstract][Full Text] [Related]
4. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy.
Dalakas MC; Rakocevic G; Salajegheh M; Dambrosia JM; Hahn AF; Raju R; McElroy B
Ann Neurol; 2009 Mar; 65(3):286-93. PubMed ID: 19334068
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies.
Renaud S; Gregor M; Fuhr P; Lorenz D; Deuschl G; Gratwohl A; Steck AJ
Muscle Nerve; 2003 May; 27(5):611-5. PubMed ID: 12707982
[TBL] [Abstract][Full Text] [Related]
6. Neurophysiological and clinical responses to rituximab in patients with anti-MAG polyneuropathy.
Zara G; Zambello R; Ermani M
Clin Neurophysiol; 2011 Dec; 122(12):2518-22. PubMed ID: 21680240
[TBL] [Abstract][Full Text] [Related]
7. Worsening after rituximab treatment in anti-mag neuropathy.
Broglio L; Lauria G
Muscle Nerve; 2005 Sep; 32(3):378-9. PubMed ID: 15986418
[No Abstract] [Full Text] [Related]
8. Remission of demyelinating polyneuropathy with immunoadsorption, low dose corticosteroids and anti-CD20 monoclonal antibody.
Rech J; Hueber AJ; Kallert S; Leipe J; Kalden JR; Beck M; Schett G; Schulze-Koops H
Ther Apher Dial; 2008 Jun; 12(3):205-8. PubMed ID: 18503697
[TBL] [Abstract][Full Text] [Related]
9. Relapses after treatment with rituximab in a patient with multiple sclerosis and anti myelin-associated glycoprotein polyneuropathy.
Benedetti L; Franciotta D; Vigo T; Grandis M; Fiorina E; Ghiglione E; Roccatagliata L; Mancardi GL; Uccelli A; Schenone A
Arch Neurol; 2007 Oct; 64(10):1531-3. PubMed ID: 17923639
[TBL] [Abstract][Full Text] [Related]
10. [Rapid improvement by rituximab treatment in a case of demyelinating polyneuropathy with anti-myelin-associated glycoprotein antibody].
Motoyama R; Yamakawa K; Suzuki S; Kusunoki S; Tanaka M
Rinsho Shinkeigaku; 2011 Oct; 51(10):761-4. PubMed ID: 22019868
[TBL] [Abstract][Full Text] [Related]
11. Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy.
Kuijf ML; Eurelings M; Tio-Gillen AP; van Doorn PA; van den Berg LH; Hooijkaas H; Stork J; Notermans NC; Jacobs BC
Neurology; 2009 Sep; 73(9):688-95. PubMed ID: 19720975
[TBL] [Abstract][Full Text] [Related]
12. Acute neurological worsening after Rituximab treatment in patients with anti-MAG neuropathy.
Sala E; Robert-Varvat F; Paul S; Camdessanché JP; Antoine JC
J Neurol Sci; 2014 Oct; 345(1-2):224-7. PubMed ID: 25115501
[TBL] [Abstract][Full Text] [Related]
13. Familial polyneuropathy with anti-myelin-associated glycoprotein antibodies.
Srinivasan J; Tseng VG; Yang D; Harris BT; Jones HR; Stommel EW
Neurology; 2005 Jun; 64(11):1983-4. PubMed ID: 15955965
[No Abstract] [Full Text] [Related]
14. Long-term efficacy of rituximab in IgM anti-myelin-associated glycoprotein neuropathy: RIMAG follow-up study.
Iancu Ferfoglia R; Guimarães-Costa R; Viala K; Musset L; Neil J; Marin B; Léger JM
J Peripher Nerv Syst; 2016 Mar; 21(1):10-4. PubMed ID: 26748872
[TBL] [Abstract][Full Text] [Related]
15. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
[TBL] [Abstract][Full Text] [Related]
16. Antibodies to myelin-associated glycoprotein (anti-Mag) in IgM amyloidosis may influence expression of neuropathy in rare patients.
Garces-Sanchez M; Dyck PJ; Kyle RA; Zeldenrust S; Wu Y; Ladha SS; Klein CJ
Muscle Nerve; 2008 Apr; 37(4):490-5. PubMed ID: 18236455
[TBL] [Abstract][Full Text] [Related]
17. Paradoxical worsening of anti–myelin-associated glycoprotein polyneuropathy following rituximab.
Weiss MD; Becker P
Muscle Nerve; 2014 Mar; 49(3):457-8. PubMed ID: 24741682
[No Abstract] [Full Text] [Related]
18. NK cells and their receptors in naive and rituximab-treated patients with anti-MAG polyneuropathy.
Benedetti L; Facco M; Franciotta D; Dalla Torre C; Campagnolo M; Lucchetta M; Boscaro E; Ermani M; Del Sette M; Berno T; Candiotto L; Zambello R; Briani C
J Neurol Sci; 2013 Aug; 331(1-2):86-9. PubMed ID: 23764364
[TBL] [Abstract][Full Text] [Related]
19. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial.
Gorson KC; Natarajan N; Ropper AH; Weinstein R
Muscle Nerve; 2007 Jan; 35(1):66-9. PubMed ID: 16967492
[TBL] [Abstract][Full Text] [Related]
20. Outcomes after single-cycle rituximab monotherapy in patients with anti-MAG polyneuropathy: A bi-center experience with an average follow-up of 11 years.
Benedetti L; Garnero M; Demichelis C; Grandis M; Briani C; Beltramini S; Bellucci M; Prada V; Massa F; Gastaldi M; Schenone A; Franciotta D
J Neuroimmunol; 2019 Dec; 337():577081. PubMed ID: 31677562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
